Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus
(T2DM), acting via indirect activation of 5′ Adenosine monophosphate-activated Protein …

Kidney cancer is the 13th most common malignancy globally, and the incidence is rising.
Papillary renal cell carcinoma is the second most common subtype, comprising 10-15% of …

Background MET (also known as hepatocyte growth factor receptor) signalling is a key
driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic …

Abstract The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal
neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide …

Importance There exists considerable biological and clinical variability between histologic
variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis …

It has been 35 years since Professor Thoenes and his colleagues discovered chromophobe
renal cell carcinoma (RCC). Since then, our knowledge about this tumour entity has …

Fifteen years since the first recognition of clear cell papillary renal cell carcinoma, this
distinct renal tumour type is now well accepted as a distinct entity in major classification …

Cystic renal masses are commonly encountered in clinical practice. In 2019, the Bosniak
classification of cystic renal masses, originally developed for CT, underwent a major revision …

Thyroid-like follicular renal cell carcinoma is an uncommon kidney tumor with no distinct
molecular alteration described to date. This cohort of eight women with mean and median …

Renal cell carcinoma (RCC) represents a heterogeneous disease, encompassing an
increasing number of tumor subtypes. Post-2016, the World Health Organization (WHO) …